The Role of the Neuro-Oncologist in EGFR-Mutant NSCLC

The Role of the Neuro-Oncologist in EGFR-Mutant NSCLC

Treating Leptomeningeal Carcinomatosis Within the Multidisciplinary Team

Not a member of My prIME? Join now for instant access.

Meeting Overview

Learn more about the role of the neuro-oncologist in the management of leptomeningeal carcinomatosis of EGFR-mutant NSCLC. Detection and diagnosis of leptomeningeal carcinomatosis (LMC) and optimal therapeutic approaches for disease management will be discussed. The audience will have the opportunity to interact with the expert multidisciplinary faculty during this activity while learning more about this challenging condition.

Date and Location

Friday, November 16, 2018
5.30 PM – 7.30 PM

Gallerie 5-6
New Orleans Marriott 555 Canal Street
New Orleans, Louisiana 70130



Friday, November 16, 2018
5.30 PM – 7.30 PM



New Orleans, Louisiana, United States



1.25 AMA PRA Category 1 Credits™

6.15 PM Welcome and introduction
Maciej Mrugala, MD, PhD, MPH
6.20 PM Interactive “Test your knowledge of LMC” quiz
Maciej Mrugala, MD, PhD, MPH
6.27 PM How can I improve detection and diagnosis of LMC?
Maciej Mrugala, MD, PhD, MPH
6.34 PM Radiotherapy for LMC: How much and when?
Helen Shih, MD, MS, MPH
6.41 PM Interactive audience Q & A: What are your burning questions?
6.46 PM Can EGFR-targeted TKIs move us beyond palliative care for LMC?
Jhanelle Gray, MD
6.59 PM How do I treat LMC in patients with EGFR-mutant NSCLC?
Barbara O’Brien, MD
7.12 PM Interactive audience Q & A: What are your burning questions?
7.17 PM Audience post-test and prIME Points™
Maciej Mrugala, MD, PhD, MPH
7.30 PM Adjourn




  • Maciej Mrugala, MD, PhD, MPHMayo Clinic
    Phoenix, Arizona, United States
  • Faculty

  • Barbara O’Brien, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Jhanelle E. Gray, MDH. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida, United States
  • Helen Shih, MD, MS, MPHMassachusetts General Hospital
    Harvard Medical School
    Boston, Massachusetts, United States

This educational activity is specifically designed to meet the needs of neuro-oncologists, neurologists, and other healthcare professionals involved/interested in the management of patients with LMC as a consequence of non-small cell lung cancer (NSCLC).

After successful completion of this educational activity, participants should be able to:

  • Evaluate strategies to improve the detection and diagnosis of LMC in patients with NSCLC
  • Analyze recent clinical trial data regarding the efficacy and safety of EGFR tyrosine kinase inhibitors (TKIs) in the treatment of LMC in NSCLC
  • Identify best practices for the use of radiotherapy to treat LMC in patients with NSCLC
  • Select optimal treatment strategies for LMC in patients with EGFR­-mutant NSCLC

This educational activity is supported by a grant from AstraZeneca.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.